5326492025-04-012025-06-305326492025-04-012025-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares532649NECLIFENOTLISTEDINE023H01027Nectar Lifesciences LimitedMain BoardEquity2025-04-012026-03-312025-08-142025-08-11INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical Business Segment2025-08-1415:00:002025-08-1416:20:00Not applicablefalsefalseThere is no default by the Company on its loans. The Company has not issued any debt securities.2025-04-012025-06-30UnauditedStandalone280671400034990002810213000236068600002747090002426350001869520001651570005476170003777756000-9675430000-9675430000-335235000-3352350000-6323080000000-6323080000-6323080002242610001-2.82-2.8200-2.82-2.82Notes:- <BR> 1. The above financial results were reviewed by Audit Committee on August 14, 2025 and approved by the Board in its meeting held on August 14, 2025. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2025. <BR> <BR> 2. The company is exclusively in the pharmaceutical business segment. <BR> <BR> 3. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. <BR> <BR> 4. The figures of the last quarter for the previous financial year i.e. March 31, 2025 are the balancing figures between the audited figure in respect of the full previous financial year ended March 31, 2025 and the unaudited published year to date figures upto the third quarter ended December 31, 2024 which was subject to limited review and not audit. <BR> <BR> 5. The Company has undertaken following transactions after the end of the quarter: <BR> i. Sale of business of manufacture, distribution, marketing and sale of active pharmaceutical ingredients and formulations (“Business”) of the Company to Ceph Lifesciences Private Limited (“Purchaser”) for INR 12,70,00,00,000/- (Indian Rupees one thousand two hundred seventy crore only) subject to adjustments in accordance with the terms of the business transfer agreement , as a slump sale on a going concern basis; and <BR> ii. Sale, transfer and delivery of the assets of the Company in relation to its menthol business (“Assets”) to Purchaser for INR 20,00,00,000/- (Indian Rupees Twenty Crores only), plus applicable GST payable on the sale of such Assets under the applicable law.Other Expenses547617000